Clinical and imaging correlates of amyloid deposition in dementia with Lewy bodies

ABSTRACT Background: Amyloid deposition is common in dementia with Lewy bodies, but its pathophysiological significance is unclear. Objective: The objective of this study was to investigate the relationship between amyloid deposition and clinical profile, gray matter volume, and brain perfusion in d...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Movement disorders 2018-07, Vol.33 (7), p.1130-1138
Hauptverfasser: Donaghy, Paul C., Firbank, Michael J, Thomas, Alan J., Lloyd, Jim, Petrides, George, Barnett, Nicola, Olsen, Kirsty, O'Brien, John T.
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 1138
container_issue 7
container_start_page 1130
container_title Movement disorders
container_volume 33
creator Donaghy, Paul C.
Firbank, Michael J
Thomas, Alan J.
Lloyd, Jim
Petrides, George
Barnett, Nicola
Olsen, Kirsty
O'Brien, John T.
description ABSTRACT Background: Amyloid deposition is common in dementia with Lewy bodies, but its pathophysiological significance is unclear. Objective: The objective of this study was to investigate the relationship between amyloid deposition and clinical profile, gray matter volume, and brain perfusion in dementia with Lewy bodies. Methods: Dementia with Lewy bodies (n = 37), Alzheimer's disease (n = 20), and controls (n = 20) underwent a thorough clinical assessment, 3T MRI, and early‐ and late‐phase 18F‐Florbetapir PET‐CT to assess cortical perfusion and amyloid deposition, respectively. Amyloid scans were visually categorized as positive or negative. Image analysis was carried out using statistical parametric mapping (SPM) 8. Results: There were no significant differences between amyloid‐positive and amyloid‐negative dementia with Lewy bodies cases in age (P = .78), overall cognitive impairment (P = .83), level of functional impairment (P = .80), or any other clinical or cognitive scale. There were also no significant differences in hippocampal or gray matter volumes. However, amyloid‐positive dementia with Lewy bodies cases had lower medial temporal lobe perfusion (P = .03) than amyloid‐negative cases, although a combination of medial temporal lobe perfusion, hippocampal volume, and cognitive measures was unable to accurately predict amyloid status in dementia with Lewy bodies. Conclusions: Amyloid deposition was not associated with differences in clinical or neuropsychological profiles in dementia with Lewy bodies, but was associated with imaging evidence of medial temporal lobe dysfunction. The presence of amyloid in dementia with Lewy bodies cannot be identified on the basis of clinical and other imaging features and will require direct assessment via PET imaging or CSF. © 2018 The Authors. Movement Disorders published by Wiley Periodicals, Inc. on behalf of International Parkinson and Movement Disorder Society.
doi_str_mv 10.1002/mds.27403
format Article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6175485</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2094675498</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4433-b72f0ef28bbbae6bc47ec7ba01adf03b99d0cdbd96f662f98d6986e1eb7d43cf3</originalsourceid><addsrcrecordid>eNp1kU1rVDEUhoModlpd-Ack4MYubpuPe3OTjVBG2wojgh_rkM9pSm4yJncc5t-bdmpRwdXhcB4e3sMLwCuMzjBC5Hyy9YyMPaJPwAIPFHecDONTsECcDx3FfDgCx7XeIoTxgNlzcEQEG4mgaAG-LGNIwagIVbIwTGod0hqaXIqLanYVZg_VtI85WGjdJtcwh5xgSG2bXJqDgrsw38CV2-2hzja4-gI88ypW9_JhnoDvlx--La-71eerj8uLVWf6ntJOj8Qj5wnXWivHtOlHZ0atEFbWI6qFsMhYbQXzjBEvuGWCM4edHm1Pjacn4N3Bu9nqyVnT0hQV5aa0L8peZhXk35cUbuQ6_5QMj0PPhyZ4-yAo-cfW1VlOoRoXo0oub6skiHAxUEp4Q9_8g97mbUntvUaJnjWhuKNOD5Qpudbi_GMYjORdU7I1Je-bauzrP9M_kr-racD5AdiF6Pb_N8lP778elL8AzZSfdg</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2094675498</pqid></control><display><type>article</type><title>Clinical and imaging correlates of amyloid deposition in dementia with Lewy bodies</title><source>MEDLINE</source><source>Access via Wiley Online Library</source><creator>Donaghy, Paul C. ; Firbank, Michael J ; Thomas, Alan J. ; Lloyd, Jim ; Petrides, George ; Barnett, Nicola ; Olsen, Kirsty ; O'Brien, John T.</creator><creatorcontrib>Donaghy, Paul C. ; Firbank, Michael J ; Thomas, Alan J. ; Lloyd, Jim ; Petrides, George ; Barnett, Nicola ; Olsen, Kirsty ; O'Brien, John T.</creatorcontrib><description>ABSTRACT Background: Amyloid deposition is common in dementia with Lewy bodies, but its pathophysiological significance is unclear. Objective: The objective of this study was to investigate the relationship between amyloid deposition and clinical profile, gray matter volume, and brain perfusion in dementia with Lewy bodies. Methods: Dementia with Lewy bodies (n = 37), Alzheimer's disease (n = 20), and controls (n = 20) underwent a thorough clinical assessment, 3T MRI, and early‐ and late‐phase 18F‐Florbetapir PET‐CT to assess cortical perfusion and amyloid deposition, respectively. Amyloid scans were visually categorized as positive or negative. Image analysis was carried out using statistical parametric mapping (SPM) 8. Results: There were no significant differences between amyloid‐positive and amyloid‐negative dementia with Lewy bodies cases in age (P = .78), overall cognitive impairment (P = .83), level of functional impairment (P = .80), or any other clinical or cognitive scale. There were also no significant differences in hippocampal or gray matter volumes. However, amyloid‐positive dementia with Lewy bodies cases had lower medial temporal lobe perfusion (P = .03) than amyloid‐negative cases, although a combination of medial temporal lobe perfusion, hippocampal volume, and cognitive measures was unable to accurately predict amyloid status in dementia with Lewy bodies. Conclusions: Amyloid deposition was not associated with differences in clinical or neuropsychological profiles in dementia with Lewy bodies, but was associated with imaging evidence of medial temporal lobe dysfunction. The presence of amyloid in dementia with Lewy bodies cannot be identified on the basis of clinical and other imaging features and will require direct assessment via PET imaging or CSF. © 2018 The Authors. Movement Disorders published by Wiley Periodicals, Inc. on behalf of International Parkinson and Movement Disorder Society.</description><identifier>ISSN: 0885-3185</identifier><identifier>EISSN: 1531-8257</identifier><identifier>DOI: 10.1002/mds.27403</identifier><identifier>PMID: 29672930</identifier><language>eng</language><publisher>United States: Wiley Subscription Services, Inc</publisher><subject>Aged ; Aged, 80 and over ; Alzheimer Disease - diagnostic imaging ; Alzheimer Disease - metabolism ; Alzheimer's disease ; amyloid ; Amyloid - metabolism ; Aniline Compounds - metabolism ; Brain - diagnostic imaging ; Brain - metabolism ; Cerebrospinal fluid ; Cognition Disorders - etiology ; Cognitive ability ; Computed tomography ; Cortex ; Dementia ; Dementia disorders ; Dementia with Lewy bodies ; England ; Ethylene Glycols - metabolism ; Female ; florbetapir ; Hippocampus ; Humans ; Image processing ; Imaging, Three-Dimensional ; Lewy bodies ; Lewy Body Disease - diagnostic imaging ; Lewy Body Disease - metabolism ; Magnetic Resonance Imaging ; Male ; Middle Aged ; Movement disorders ; Neurodegenerative diseases ; Neuroimaging ; Perfusion ; Positron emission tomography ; Prospective Studies ; Substantia grisea ; Temporal lobe ; Tomography Scanners, X-Ray Computed</subject><ispartof>Movement disorders, 2018-07, Vol.33 (7), p.1130-1138</ispartof><rights>2018 The Authors. Movement Disorders published by Wiley Periodicals, Inc. on behalf of International Parkinson and Movement Disorder Society.</rights><rights>2018 International Parkinson and Movement Disorder Society</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4433-b72f0ef28bbbae6bc47ec7ba01adf03b99d0cdbd96f662f98d6986e1eb7d43cf3</citedby><cites>FETCH-LOGICAL-c4433-b72f0ef28bbbae6bc47ec7ba01adf03b99d0cdbd96f662f98d6986e1eb7d43cf3</cites><orcidid>0000-0001-7195-4846</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1002%2Fmds.27403$$EPDF$$P50$$Gwiley$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1002%2Fmds.27403$$EHTML$$P50$$Gwiley$$Hfree_for_read</linktohtml><link.rule.ids>230,314,780,784,885,1417,27924,27925,45574,45575</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/29672930$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Donaghy, Paul C.</creatorcontrib><creatorcontrib>Firbank, Michael J</creatorcontrib><creatorcontrib>Thomas, Alan J.</creatorcontrib><creatorcontrib>Lloyd, Jim</creatorcontrib><creatorcontrib>Petrides, George</creatorcontrib><creatorcontrib>Barnett, Nicola</creatorcontrib><creatorcontrib>Olsen, Kirsty</creatorcontrib><creatorcontrib>O'Brien, John T.</creatorcontrib><title>Clinical and imaging correlates of amyloid deposition in dementia with Lewy bodies</title><title>Movement disorders</title><addtitle>Mov Disord</addtitle><description>ABSTRACT Background: Amyloid deposition is common in dementia with Lewy bodies, but its pathophysiological significance is unclear. Objective: The objective of this study was to investigate the relationship between amyloid deposition and clinical profile, gray matter volume, and brain perfusion in dementia with Lewy bodies. Methods: Dementia with Lewy bodies (n = 37), Alzheimer's disease (n = 20), and controls (n = 20) underwent a thorough clinical assessment, 3T MRI, and early‐ and late‐phase 18F‐Florbetapir PET‐CT to assess cortical perfusion and amyloid deposition, respectively. Amyloid scans were visually categorized as positive or negative. Image analysis was carried out using statistical parametric mapping (SPM) 8. Results: There were no significant differences between amyloid‐positive and amyloid‐negative dementia with Lewy bodies cases in age (P = .78), overall cognitive impairment (P = .83), level of functional impairment (P = .80), or any other clinical or cognitive scale. There were also no significant differences in hippocampal or gray matter volumes. However, amyloid‐positive dementia with Lewy bodies cases had lower medial temporal lobe perfusion (P = .03) than amyloid‐negative cases, although a combination of medial temporal lobe perfusion, hippocampal volume, and cognitive measures was unable to accurately predict amyloid status in dementia with Lewy bodies. Conclusions: Amyloid deposition was not associated with differences in clinical or neuropsychological profiles in dementia with Lewy bodies, but was associated with imaging evidence of medial temporal lobe dysfunction. The presence of amyloid in dementia with Lewy bodies cannot be identified on the basis of clinical and other imaging features and will require direct assessment via PET imaging or CSF. © 2018 The Authors. Movement Disorders published by Wiley Periodicals, Inc. on behalf of International Parkinson and Movement Disorder Society.</description><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Alzheimer Disease - diagnostic imaging</subject><subject>Alzheimer Disease - metabolism</subject><subject>Alzheimer's disease</subject><subject>amyloid</subject><subject>Amyloid - metabolism</subject><subject>Aniline Compounds - metabolism</subject><subject>Brain - diagnostic imaging</subject><subject>Brain - metabolism</subject><subject>Cerebrospinal fluid</subject><subject>Cognition Disorders - etiology</subject><subject>Cognitive ability</subject><subject>Computed tomography</subject><subject>Cortex</subject><subject>Dementia</subject><subject>Dementia disorders</subject><subject>Dementia with Lewy bodies</subject><subject>England</subject><subject>Ethylene Glycols - metabolism</subject><subject>Female</subject><subject>florbetapir</subject><subject>Hippocampus</subject><subject>Humans</subject><subject>Image processing</subject><subject>Imaging, Three-Dimensional</subject><subject>Lewy bodies</subject><subject>Lewy Body Disease - diagnostic imaging</subject><subject>Lewy Body Disease - metabolism</subject><subject>Magnetic Resonance Imaging</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Movement disorders</subject><subject>Neurodegenerative diseases</subject><subject>Neuroimaging</subject><subject>Perfusion</subject><subject>Positron emission tomography</subject><subject>Prospective Studies</subject><subject>Substantia grisea</subject><subject>Temporal lobe</subject><subject>Tomography Scanners, X-Ray Computed</subject><issn>0885-3185</issn><issn>1531-8257</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2018</creationdate><recordtype>article</recordtype><sourceid>24P</sourceid><sourceid>WIN</sourceid><sourceid>EIF</sourceid><recordid>eNp1kU1rVDEUhoModlpd-Ack4MYubpuPe3OTjVBG2wojgh_rkM9pSm4yJncc5t-bdmpRwdXhcB4e3sMLwCuMzjBC5Hyy9YyMPaJPwAIPFHecDONTsECcDx3FfDgCx7XeIoTxgNlzcEQEG4mgaAG-LGNIwagIVbIwTGod0hqaXIqLanYVZg_VtI85WGjdJtcwh5xgSG2bXJqDgrsw38CV2-2hzja4-gI88ypW9_JhnoDvlx--La-71eerj8uLVWf6ntJOj8Qj5wnXWivHtOlHZ0atEFbWI6qFsMhYbQXzjBEvuGWCM4edHm1Pjacn4N3Bu9nqyVnT0hQV5aa0L8peZhXk35cUbuQ6_5QMj0PPhyZ4-yAo-cfW1VlOoRoXo0oub6skiHAxUEp4Q9_8g97mbUntvUaJnjWhuKNOD5Qpudbi_GMYjORdU7I1Je-bauzrP9M_kr-racD5AdiF6Pb_N8lP778elL8AzZSfdg</recordid><startdate>201807</startdate><enddate>201807</enddate><creator>Donaghy, Paul C.</creator><creator>Firbank, Michael J</creator><creator>Thomas, Alan J.</creator><creator>Lloyd, Jim</creator><creator>Petrides, George</creator><creator>Barnett, Nicola</creator><creator>Olsen, Kirsty</creator><creator>O'Brien, John T.</creator><general>Wiley Subscription Services, Inc</general><general>John Wiley and Sons Inc</general><scope>24P</scope><scope>WIN</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7TK</scope><scope>8FD</scope><scope>FR3</scope><scope>K9.</scope><scope>NAPCQ</scope><scope>P64</scope><scope>RC3</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0001-7195-4846</orcidid></search><sort><creationdate>201807</creationdate><title>Clinical and imaging correlates of amyloid deposition in dementia with Lewy bodies</title><author>Donaghy, Paul C. ; Firbank, Michael J ; Thomas, Alan J. ; Lloyd, Jim ; Petrides, George ; Barnett, Nicola ; Olsen, Kirsty ; O'Brien, John T.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4433-b72f0ef28bbbae6bc47ec7ba01adf03b99d0cdbd96f662f98d6986e1eb7d43cf3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2018</creationdate><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Alzheimer Disease - diagnostic imaging</topic><topic>Alzheimer Disease - metabolism</topic><topic>Alzheimer's disease</topic><topic>amyloid</topic><topic>Amyloid - metabolism</topic><topic>Aniline Compounds - metabolism</topic><topic>Brain - diagnostic imaging</topic><topic>Brain - metabolism</topic><topic>Cerebrospinal fluid</topic><topic>Cognition Disorders - etiology</topic><topic>Cognitive ability</topic><topic>Computed tomography</topic><topic>Cortex</topic><topic>Dementia</topic><topic>Dementia disorders</topic><topic>Dementia with Lewy bodies</topic><topic>England</topic><topic>Ethylene Glycols - metabolism</topic><topic>Female</topic><topic>florbetapir</topic><topic>Hippocampus</topic><topic>Humans</topic><topic>Image processing</topic><topic>Imaging, Three-Dimensional</topic><topic>Lewy bodies</topic><topic>Lewy Body Disease - diagnostic imaging</topic><topic>Lewy Body Disease - metabolism</topic><topic>Magnetic Resonance Imaging</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Movement disorders</topic><topic>Neurodegenerative diseases</topic><topic>Neuroimaging</topic><topic>Perfusion</topic><topic>Positron emission tomography</topic><topic>Prospective Studies</topic><topic>Substantia grisea</topic><topic>Temporal lobe</topic><topic>Tomography Scanners, X-Ray Computed</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Donaghy, Paul C.</creatorcontrib><creatorcontrib>Firbank, Michael J</creatorcontrib><creatorcontrib>Thomas, Alan J.</creatorcontrib><creatorcontrib>Lloyd, Jim</creatorcontrib><creatorcontrib>Petrides, George</creatorcontrib><creatorcontrib>Barnett, Nicola</creatorcontrib><creatorcontrib>Olsen, Kirsty</creatorcontrib><creatorcontrib>O'Brien, John T.</creatorcontrib><collection>Wiley Online Library (Open Access Collection)</collection><collection>Wiley Online Library (Open Access Collection)</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Neurosciences Abstracts</collection><collection>Technology Research Database</collection><collection>Engineering Research Database</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Nursing &amp; Allied Health Premium</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>Genetics Abstracts</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Movement disorders</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Donaghy, Paul C.</au><au>Firbank, Michael J</au><au>Thomas, Alan J.</au><au>Lloyd, Jim</au><au>Petrides, George</au><au>Barnett, Nicola</au><au>Olsen, Kirsty</au><au>O'Brien, John T.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Clinical and imaging correlates of amyloid deposition in dementia with Lewy bodies</atitle><jtitle>Movement disorders</jtitle><addtitle>Mov Disord</addtitle><date>2018-07</date><risdate>2018</risdate><volume>33</volume><issue>7</issue><spage>1130</spage><epage>1138</epage><pages>1130-1138</pages><issn>0885-3185</issn><eissn>1531-8257</eissn><abstract>ABSTRACT Background: Amyloid deposition is common in dementia with Lewy bodies, but its pathophysiological significance is unclear. Objective: The objective of this study was to investigate the relationship between amyloid deposition and clinical profile, gray matter volume, and brain perfusion in dementia with Lewy bodies. Methods: Dementia with Lewy bodies (n = 37), Alzheimer's disease (n = 20), and controls (n = 20) underwent a thorough clinical assessment, 3T MRI, and early‐ and late‐phase 18F‐Florbetapir PET‐CT to assess cortical perfusion and amyloid deposition, respectively. Amyloid scans were visually categorized as positive or negative. Image analysis was carried out using statistical parametric mapping (SPM) 8. Results: There were no significant differences between amyloid‐positive and amyloid‐negative dementia with Lewy bodies cases in age (P = .78), overall cognitive impairment (P = .83), level of functional impairment (P = .80), or any other clinical or cognitive scale. There were also no significant differences in hippocampal or gray matter volumes. However, amyloid‐positive dementia with Lewy bodies cases had lower medial temporal lobe perfusion (P = .03) than amyloid‐negative cases, although a combination of medial temporal lobe perfusion, hippocampal volume, and cognitive measures was unable to accurately predict amyloid status in dementia with Lewy bodies. Conclusions: Amyloid deposition was not associated with differences in clinical or neuropsychological profiles in dementia with Lewy bodies, but was associated with imaging evidence of medial temporal lobe dysfunction. The presence of amyloid in dementia with Lewy bodies cannot be identified on the basis of clinical and other imaging features and will require direct assessment via PET imaging or CSF. © 2018 The Authors. Movement Disorders published by Wiley Periodicals, Inc. on behalf of International Parkinson and Movement Disorder Society.</abstract><cop>United States</cop><pub>Wiley Subscription Services, Inc</pub><pmid>29672930</pmid><doi>10.1002/mds.27403</doi><tpages>9</tpages><orcidid>https://orcid.org/0000-0001-7195-4846</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0885-3185
ispartof Movement disorders, 2018-07, Vol.33 (7), p.1130-1138
issn 0885-3185
1531-8257
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6175485
source MEDLINE; Access via Wiley Online Library
subjects Aged
Aged, 80 and over
Alzheimer Disease - diagnostic imaging
Alzheimer Disease - metabolism
Alzheimer's disease
amyloid
Amyloid - metabolism
Aniline Compounds - metabolism
Brain - diagnostic imaging
Brain - metabolism
Cerebrospinal fluid
Cognition Disorders - etiology
Cognitive ability
Computed tomography
Cortex
Dementia
Dementia disorders
Dementia with Lewy bodies
England
Ethylene Glycols - metabolism
Female
florbetapir
Hippocampus
Humans
Image processing
Imaging, Three-Dimensional
Lewy bodies
Lewy Body Disease - diagnostic imaging
Lewy Body Disease - metabolism
Magnetic Resonance Imaging
Male
Middle Aged
Movement disorders
Neurodegenerative diseases
Neuroimaging
Perfusion
Positron emission tomography
Prospective Studies
Substantia grisea
Temporal lobe
Tomography Scanners, X-Ray Computed
title Clinical and imaging correlates of amyloid deposition in dementia with Lewy bodies
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-03T22%3A26%3A18IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Clinical%20and%20imaging%20correlates%20of%20amyloid%20deposition%20in%20dementia%20with%20Lewy%20bodies&rft.jtitle=Movement%20disorders&rft.au=Donaghy,%20Paul%20C.&rft.date=2018-07&rft.volume=33&rft.issue=7&rft.spage=1130&rft.epage=1138&rft.pages=1130-1138&rft.issn=0885-3185&rft.eissn=1531-8257&rft_id=info:doi/10.1002/mds.27403&rft_dat=%3Cproquest_pubme%3E2094675498%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2094675498&rft_id=info:pmid/29672930&rfr_iscdi=true